Quick Answer
Kalaris Therapeutics, Inc. reported Cash and Equivalents of $98.05 million for fiscal year 2025.
Kalaris Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $98.05M | +5882.6% |
| 2024 | $1.64M | -98.2% |
| 2023 | $90.12M | -15.1% |
| 2022 | $106.09M | -47.4% |
| 2021 | $201.66M | +64.4% |
| 2020 | $122.66M | +100.8% |
| 2019 | $61.08M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $42.39M | +2115.7% | -52.1% |
| June 30, 2025 | $88.43M | +1317.3% | -12.4% |
| March 31, 2025 | $100.97M | +1831.6% | +6060.2% |
| December 31, 2024 | $1.64M | -98.2% | -14.3% |
| September 30, 2024 | $1.91M | -98.0% | -69.3% |
| June 30, 2024 | $6.24M | -96.8% | +19.4% |
| March 31, 2024 | $5.23M | -95.5% | -94.2% |
| December 31, 2023 | $90.12M | -15.1% | -5.8% |
- Kalaris Therapeutics, Inc. showed an increase of +5882.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Kalaris Therapeutics, Inc.’s cash and equivalents has grown by 60.5% (from $61.08 million to $98.05 million).
- The most recent figure is from Kalaris Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: